Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5883058 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 9 Pages |
Abstract
Myelofibrosis (MF) is characterized by splenomegaly, blood count abnormalities, particularly cytopenias, and a propensity for transformation to acute leukemia. The current treatment approach is to ameliorate symptoms due to these abnormalities. Treatment with Janus kinase 2 inhibitors reduces spleen size and improves symptoms in patients with MF, but most of the patients eventually have disease progression and stop responding. Allogeneic stem cell transplantation remains the only curative option. However, its efficacy must be balanced against the risk of treatment-related death and long-term sequelae of transplant like chronic graft versus host disease. The challenge is to integrate treatment with Janus kinase inhibitors with allogeneic stem cell transplantation.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Riad El Fakih, Uday Popat,